NeutriSci International Inc. (TSXV:NU) (OTCQB: NRXCF) (FSE: 1N9) (the “Company” or “NeutriSci”), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. (“Scientus Pharma”). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada.
The core ingredients in NeutriSci’s products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research on Neutrisci’s products and their components in combination with various cannabinoids. Research activities will initially be funded by Neutrisci. Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded.
NeutriSci President Mr. Glen Rehman stated, “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that completes our ‘plant to blood stream’ strategy.”
“Neutrisci brings a wealth of retail distribution and consumer branding expertise,” said Scientus Chairman Mr. Har Grover. “They have had success innovating with neuenergy and the brand has good presence in several health and wellness settings. Pterostilbene and related compounds present interesting targets for further research and we are looking forward to this collaboration.”
About Scientus Pharma
Hydrx Farms Ltd. O/A Scientus Pharma is a vertically-integrated biopharmaceutical Licensed Dealer under the Narcotics Control Regulations promulgated under the Controlled Drugs and Substances Act (Canada) with a focus on developing and commercializing pharmaceutical-grade medicinal cannabinoid derivative products. Being one of a limited number of Licensed Dealers in Canada authorized to handle cannabinoid products, Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives from and to Licensed Producers, as well as international markets. The company recently received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license from Health Canada.
www.scientuspharma.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci is currently focussed on increasing the size of its existing national retail network in Canada by building sustainable sales models with Convenience, Chain Drug, Mass Market and Supermarket retailers for neuenergy® and new novel ingredients for product distribution. It also continues to develop emerging sales channels in the US, Europe and Asia.
www.neutrisci.com
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO & President
Tel: (403) 264-6320
Email: grehman@neutrisci.com
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forwardlooking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forwardlooking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forwardlooking statements. Factors that could cause actual results to differ materially from those in forwardlooking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forwardlooking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
Click here to connect with NeutriSci International Inc. (TSXV:NU)  to receive an Investor Presentation

Source: www.newsfilecorp.com


Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (FSE: XJCB) (“Centurion” or the “Company”) is pleased to announce that it has entered into an Amalgamation Agreement dated February 17, 2021 (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion will acquire 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less